Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated igf-1 but normal glucose-suppressed growth hormone

Sreevidya K. Subbarayan, Maria Fleseriu, Murray B. Gordon, Jessica A. Brzana, Laurence Kennedy, Charles Faiman, Betul A. Hatipoglu, Richard A. Prayson, Johnny B. Delashaw, Robert J. Weil, Amir H. Hamrahian

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: To report the utility of insulin-like growth factor-1 (IGF-1) as a single biomarker for establishing the diagnosis of acromegaly and to examine the clinical and biochemical profile of patients with an elevated IGF-1 in whom a diagnosis of acromegaly could not be confirmed by means of the oral glucose tolerance test (OGTT). Methods: Between the years 1999 and 2010, we identified 101 patients who underwent pituitary surgery and had histologically proven somatotroph adenomas (Group 1, Gr 1). We selected 149 patients with non-growth hormone (GH) secreting pituitary macroadenomas (Gr 2, n = 97) and microadenomas (Gr 3, n = 52) to serve as control subjects. In addition, we identified 34 patients with elevated IGF-1values in whom acromegaly could not subsequently be proven by the OGTT (Gr 4). Results: IGF-1 was elevated in all patients with acromegaly prior to therapy with a median (range) standard deviation score (SDS) of +9.52 (+2.34 to +9.2), compared to SDS -1.46 (-2.91 to +2.17) and -1.22 (-2.8 to +1.58) in Gr 2 and 3, respectively (P

Original languageEnglish (US)
Pages (from-to)817-825
Number of pages9
JournalEndocrine Practice
Volume18
Issue number6
DOIs
StatePublished - Nov 1 2012

Fingerprint

Acromegaly
Somatomedins
Growth Hormone
Glucose
Serum
Glucose Tolerance Test
Growth Hormone-Secreting Pituitary Adenoma
Pituitary Hormones
Biomarkers

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated igf-1 but normal glucose-suppressed growth hormone. / Subbarayan, Sreevidya K.; Fleseriu, Maria; Gordon, Murray B.; Brzana, Jessica A.; Kennedy, Laurence; Faiman, Charles; Hatipoglu, Betul A.; Prayson, Richard A.; Delashaw, Johnny B.; Weil, Robert J.; Hamrahian, Amir H.

In: Endocrine Practice, Vol. 18, No. 6, 01.11.2012, p. 817-825.

Research output: Contribution to journalArticle

Subbarayan, SK, Fleseriu, M, Gordon, MB, Brzana, JA, Kennedy, L, Faiman, C, Hatipoglu, BA, Prayson, RA, Delashaw, JB, Weil, RJ & Hamrahian, AH 2012, 'Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated igf-1 but normal glucose-suppressed growth hormone', Endocrine Practice, vol. 18, no. 6, pp. 817-825. https://doi.org/10.4158/EP11324.OR
Subbarayan, Sreevidya K. ; Fleseriu, Maria ; Gordon, Murray B. ; Brzana, Jessica A. ; Kennedy, Laurence ; Faiman, Charles ; Hatipoglu, Betul A. ; Prayson, Richard A. ; Delashaw, Johnny B. ; Weil, Robert J. ; Hamrahian, Amir H. / Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated igf-1 but normal glucose-suppressed growth hormone. In: Endocrine Practice. 2012 ; Vol. 18, No. 6. pp. 817-825.
@article{0e91963a131d4103b2048ad4e9cb4dc6,
title = "Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated igf-1 but normal glucose-suppressed growth hormone",
abstract = "Objective: To report the utility of insulin-like growth factor-1 (IGF-1) as a single biomarker for establishing the diagnosis of acromegaly and to examine the clinical and biochemical profile of patients with an elevated IGF-1 in whom a diagnosis of acromegaly could not be confirmed by means of the oral glucose tolerance test (OGTT). Methods: Between the years 1999 and 2010, we identified 101 patients who underwent pituitary surgery and had histologically proven somatotroph adenomas (Group 1, Gr 1). We selected 149 patients with non-growth hormone (GH) secreting pituitary macroadenomas (Gr 2, n = 97) and microadenomas (Gr 3, n = 52) to serve as control subjects. In addition, we identified 34 patients with elevated IGF-1values in whom acromegaly could not subsequently be proven by the OGTT (Gr 4). Results: IGF-1 was elevated in all patients with acromegaly prior to therapy with a median (range) standard deviation score (SDS) of +9.52 (+2.34 to +9.2), compared to SDS -1.46 (-2.91 to +2.17) and -1.22 (-2.8 to +1.58) in Gr 2 and 3, respectively (P",
author = "Subbarayan, {Sreevidya K.} and Maria Fleseriu and Gordon, {Murray B.} and Brzana, {Jessica A.} and Laurence Kennedy and Charles Faiman and Hatipoglu, {Betul A.} and Prayson, {Richard A.} and Delashaw, {Johnny B.} and Weil, {Robert J.} and Hamrahian, {Amir H.}",
year = "2012",
month = "11",
day = "1",
doi = "10.4158/EP11324.OR",
language = "English (US)",
volume = "18",
pages = "817--825",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "6",

}

TY - JOUR

T1 - Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated igf-1 but normal glucose-suppressed growth hormone

AU - Subbarayan, Sreevidya K.

AU - Fleseriu, Maria

AU - Gordon, Murray B.

AU - Brzana, Jessica A.

AU - Kennedy, Laurence

AU - Faiman, Charles

AU - Hatipoglu, Betul A.

AU - Prayson, Richard A.

AU - Delashaw, Johnny B.

AU - Weil, Robert J.

AU - Hamrahian, Amir H.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Objective: To report the utility of insulin-like growth factor-1 (IGF-1) as a single biomarker for establishing the diagnosis of acromegaly and to examine the clinical and biochemical profile of patients with an elevated IGF-1 in whom a diagnosis of acromegaly could not be confirmed by means of the oral glucose tolerance test (OGTT). Methods: Between the years 1999 and 2010, we identified 101 patients who underwent pituitary surgery and had histologically proven somatotroph adenomas (Group 1, Gr 1). We selected 149 patients with non-growth hormone (GH) secreting pituitary macroadenomas (Gr 2, n = 97) and microadenomas (Gr 3, n = 52) to serve as control subjects. In addition, we identified 34 patients with elevated IGF-1values in whom acromegaly could not subsequently be proven by the OGTT (Gr 4). Results: IGF-1 was elevated in all patients with acromegaly prior to therapy with a median (range) standard deviation score (SDS) of +9.52 (+2.34 to +9.2), compared to SDS -1.46 (-2.91 to +2.17) and -1.22 (-2.8 to +1.58) in Gr 2 and 3, respectively (P

AB - Objective: To report the utility of insulin-like growth factor-1 (IGF-1) as a single biomarker for establishing the diagnosis of acromegaly and to examine the clinical and biochemical profile of patients with an elevated IGF-1 in whom a diagnosis of acromegaly could not be confirmed by means of the oral glucose tolerance test (OGTT). Methods: Between the years 1999 and 2010, we identified 101 patients who underwent pituitary surgery and had histologically proven somatotroph adenomas (Group 1, Gr 1). We selected 149 patients with non-growth hormone (GH) secreting pituitary macroadenomas (Gr 2, n = 97) and microadenomas (Gr 3, n = 52) to serve as control subjects. In addition, we identified 34 patients with elevated IGF-1values in whom acromegaly could not subsequently be proven by the OGTT (Gr 4). Results: IGF-1 was elevated in all patients with acromegaly prior to therapy with a median (range) standard deviation score (SDS) of +9.52 (+2.34 to +9.2), compared to SDS -1.46 (-2.91 to +2.17) and -1.22 (-2.8 to +1.58) in Gr 2 and 3, respectively (P

UR - http://www.scopus.com/inward/record.url?scp=84871366665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871366665&partnerID=8YFLogxK

U2 - 10.4158/EP11324.OR

DO - 10.4158/EP11324.OR

M3 - Article

VL - 18

SP - 817

EP - 825

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 6

ER -